In recent years, a number of gene expression signatures have been developed in an attempt to classify the likely prognosis and/or response to therapy for patients with invasive breast cancer better than can currently be done with standard histopathologic features, such as tumor size, tumor grade, ER and HER2 status [16]. The gene discussed is ESR1; the disease is invasive breast carcinoma.